- Home
- TXG vs DNTH Comparison
TXG vs DNTH Comparison
Compare TXG & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXG
- DNTH
- Stock Information
- Founded
- TXG 2012
- DNTH 2015
- Country
- TXG United States
- DNTH United States
- Employees
- TXG N/A
- DNTH N/A
- Industry
- TXG Biotechnology: Laboratory Analytical Instruments
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- TXG Industrials
- DNTH Health Care
- Exchange
- TXG Nasdaq
- DNTH Nasdaq
- Market Cap
- TXG 1.6B
- DNTH 1.8B
- IPO Year
- TXG 2019
- DNTH N/A
- Fundamental
- Price
- TXG $15.76
- DNTH $41.80
- Analyst Decision
- TXG Buy
- DNTH Strong Buy
- Analyst Count
- TXG 13
- DNTH 10
- Target Price
- TXG $14.50
- DNTH $68.00
- AVG Volume (30 Days)
- TXG 3.1M
- DNTH 550.0K
- Earning Date
- TXG 11-06-2025
- DNTH 11-05-2025
- Dividend Yield
- TXG N/A
- DNTH N/A
- EPS Growth
- TXG N/A
- DNTH N/A
- EPS
- TXG N/A
- DNTH N/A
- Revenue
- TXG $641,814,000.00
- DNTH $3,078,000.00
- Revenue This Year
- TXG $2.07
- DNTH N/A
- Revenue Next Year
- TXG N/A
- DNTH N/A
- P/E Ratio
- TXG N/A
- DNTH N/A
- Revenue Growth
- TXG 1.92
- DNTH N/A
- 52 Week Low
- TXG $6.78
- DNTH $13.37
- 52 Week High
- TXG $17.70
- DNTH $43.56
- Technical
- Relative Strength Index (RSI)
- TXG 61.04
- DNTH 67.23
- Support Level
- TXG $15.12
- DNTH $34.29
- Resistance Level
- TXG $17.70
- DNTH $39.11
- Average True Range (ATR)
- TXG 1.01
- DNTH 2.40
- MACD
- TXG 0.22
- DNTH 0.67
- Stochastic Oscillator
- TXG 64.37
- DNTH 83.32
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.